Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 4/20 | 0.45 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.45 |
| ▸ | DRD4 | P21917 | 5/20 | 0.42 |
| ▸ | DRD3 | P35462 | 3/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | ACKR3 | P25106 | 1/20 | 0.39 |
| ▸ | KIT | P10721 | 1/20 | 0.38 |
| ▸ | TP53 | P04637 | 2/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4616739 | 0.88 | DRD2 (0.46) | DRD2ADRA1ADRD4DRD3TP53 | |
| SCHEMBL4617142 | 0.88 | DRD2 (0.59) | DRD2ADRA1AACKR3 | |
| SCHEMBL4617776 | 0.87 | DRD2 (0.51) | DRD2ADRA1ADRD4DRD3KMT2A | |
| SCHEMBL4636194 | 0.87 | DRD2 (0.43) | DRD2ADRA1ADRD4DRD3KMT2A | |
| SCHEMBL4617186 | 0.86 | HSP90AA1 (0.46) | DRD2ADRA1AACKR3 | |
| SCHEMBL4617188 | 0.86 | DRD2 (0.43) | DRD2ADRA1ADRD4ACKR3TP53 | |
| SCHEMBL4615106 | 0.83 | DRD2 (0.53) | DRD2ADRA1ADRD4KMT2AACKR3 | |
| SCHEMBL4617785 | 0.83 | DRD2 (0.44) | DRD2ADRA1ADRD4KMT2AACKR3 | |
| SCHEMBL4615785 | 0.83 | DRD2 (0.58) | DRD2ADRA1ADRD4DRD3KMT2A | |
| SCHEMBL4616723 | 0.80 | PLK4 (0.39) | DRD2DRD4DRD3KMT2ASIGMAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080139555-A1 | Arylthiobenzylpiperidine Derivatives | H. LUNDBECK A/S (DK) | 2008-06-12 | — | — | US | disclosed |
| US-7329656-B2 | Arylthiobenzylpiperidine derivatives | H. LUNDBECK A/S (DK) | 2008-02-12 | — | — | US | disclosed |
| EP-1799223-A4 | ARYLTHIOBENZYLPIPERIDINE DERIVATES | LUNDBECK & CO AS H (DK) | 2008-01-23 | — | — | EP | disclosed |
| EP-1799223-A2 | ARYLTHIOBENZYLPIPERIDINE DERIVATES | H.Lundbeck A/S (DK) | 2007-06-27 | — | — | EP | disclosed |
| WO-2006041635-A2 | ARYLTHIOBENZYLPIPERIDINE DERIVATIVES | H. LUNDBECK A/S (DK) | 2006-04-20 | — | — | WO | disclosed |
| US-20060079683-A1 | Arylthiobenzylpiperidine derivatives | H. LUNDBECK A/S (DK) | 2006-04-13 | — | — | US | disclosed |
| US-20060079523-A1 | N-[3-(1-{[4-(4-fluorophenylthio)phenyl]methyl}(4-piperidyl))-4-methylphenyl]-2-methylpropanamide; melatonin-concentrating hormone (MCH1) receptor ligand; antidepressant, anxiolytic, antidiabetic agent | H. LUNDBECK A/S | 2006-04-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060079523-A1 | N-[3-(1-{[4-(4-fluorophenylthio)phenyl]methyl}(4-piperidyl))-4-methylphenyl]-2-methylpropanamide; melatonin-concentrating hormone (MCH1) receptor ligand; antidepressant, anxiolytic, antidiabetic agent | MCHR1, MTNR1A, MTNR1B | DRD2 156/4885ADRA1A 75/4885DRD4 129/4885 |
| US-20080139555-A1 | Arylthiobenzylpiperidine Derivatives | MCHR1, MC4R, MCHR2 | DRD2 210/4885ADRA1A 54/4885DRD4 167/4885 |
| US-20060079683-A1 | Arylthiobenzylpiperidine derivatives | MCHR1, MC4R, MCHR2 | DRD2 217/4885ADRA1A 50/4885DRD4 167/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.